Vaccine Adjuvants - Global Market Outlook (2017-2026)
According toStratistics MRC, the Global Vaccine Adjuvants Market is accounted for $460.21 million in 2017 and is expected toreach $1,330.25 million by 2026 growing at a CAGR of 12.5% from 2017 to2026. Some of the factors such as the high occurrence of zoonotic and infectious syndromes, growing geriatric population and rising usage of Adjuvants in Vaccine are fueling the market growth. However, factors such as the cost of adjuvant development and side effects of adjuvants are hampering the market growth. The rising usage of synthetic vaccines and recombinant sub-unit are acting as an opportunity for the market growth in the coming years.
Adjuvants are fundamentally compounds that improve the body’s immunogenic reaction against antigens. As a result, these are majorly added tovaccines toincrease their capability toinfluence long-term protection and safety against any kind of viruses. Currently, MF59 and aluminum salts are the only adjuvants which are viable for human usage. There have been a lot of developments done on the antigen discovery over the past decade which has enhanced the vaccine development process.
Amongst Route of Administration, Intramuscular Route segment is driven by owing torapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc. By geography, North America region is dominated the market during the forecast period due tofactors such as higher adoption, greater knowledge about regular vaccination and presence of major market players, coupled with higher healthcare expenditure.
Some of the key players in Vaccine Adjuvants market include Viscogel AB, Vaxliant, Vaxine Pty Ltd., Sigma Aldrich (Merck KGaA), Sergeant Adjuvants, OZ Biosciences, Novavax, Inc., Novartis/CSL, MVP Laboratories, Inc., Kineta, Inc., Invivogen, GSK, CureVac AG, CSL Limited, Avanti Polar Lipids, Aphios Corp., Agenus, Inc., Adjuvatis and Adjuvance Technologies, Inc.
Products Covered:
All the customers of this report will be entitled toreceive one of the following free customization options:
Adjuvants are fundamentally compounds that improve the body’s immunogenic reaction against antigens. As a result, these are majorly added tovaccines toincrease their capability toinfluence long-term protection and safety against any kind of viruses. Currently, MF59 and aluminum salts are the only adjuvants which are viable for human usage. There have been a lot of developments done on the antigen discovery over the past decade which has enhanced the vaccine development process.
Amongst Route of Administration, Intramuscular Route segment is driven by owing torapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc. By geography, North America region is dominated the market during the forecast period due tofactors such as higher adoption, greater knowledge about regular vaccination and presence of major market players, coupled with higher healthcare expenditure.
Some of the key players in Vaccine Adjuvants market include Viscogel AB, Vaxliant, Vaxine Pty Ltd., Sigma Aldrich (Merck KGaA), Sergeant Adjuvants, OZ Biosciences, Novavax, Inc., Novartis/CSL, MVP Laboratories, Inc., Kineta, Inc., Invivogen, GSK, CureVac AG, CSL Limited, Avanti Polar Lipids, Aphios Corp., Agenus, Inc., Adjuvatis and Adjuvance Technologies, Inc.
Products Covered:
- Pathogen Components
- Particulate Adjuvants
- Combination Adjuvants
- Adjuvant Emulsions
- Saponin
- Other Types
- Cancer
- Infectious Diseases
- Other Disease Types
- Virus-like Particles
- Tensoactive Adjuvants
- Organic Adjuvants
- Mineral Salt based Adjuvants
- Liposomes
- Emulsions
- Carbohydrates Adjuvants
- Bacteria-derived Adjuvants
- Other Types
- Vehicle Adjuvants
- Carriers
- Active Immunostimulants
- Subcutaneous Route
- Oral Route
- Intranasal Route
- Intramuscular Route
- Intradermal Route
- Other Route of Administrations
- Veterinary Vaccine Adjuvants
- Human Vaccine Adjuvants
- Research Institutes
- Pharmaceutical Companies
- Contract Manufacturing Organization
- Commercial
- Pediatric
- Adults
- Other End Users
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
All the customers of this report will be entitled toreceive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to3)
- SWOT Analysis of key players (up to3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Futuristic Market Scenario
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT
5.1 Introduction
5.2 Pathogen Components
5.3 Particulate Adjuvants
5.4 Combination Adjuvants
5.5 Adjuvant Emulsions
5.6 Saponin
5.7 Other Types
6 GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
6.1 Introduction
6.2 Cancer
6.3 Infectious Diseases
6.4 Other Disease Types
7 GLOBAL VACCINE ADJUVANTS MARKET, BY TYPE
7.1 Introduction
7.2 Virus-like Particles
7.3 Tensoactive Adjuvants
7.4 Organic Adjuvants
7.5 Mineral Salt based Adjuvants
7.6 Liposomes
7.7 Emulsions
7.8 Carbohydrates Adjuvants
7.9 Bacteria-derived Adjuvants
7.10 Other Types
8 GLOBAL VACCINE ADJUVANTS MARKET, BY MECHANISM OF ACTION
8.1 Introduction
8.2 Vehicle Adjuvants
8.3 Carriers
8.4 Active Immunostimulants
9 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION
9.1 Introduction
9.2 Subcutaneous Route
9.3 Oral Route
9.4 Intranasal Route
9.5 Intramuscular Route
9.6 Intradermal Route
9.7 Other Route of Administrations
10 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION
10.1 Introduction
10.2 Veterinary Vaccine Adjuvants
10.3 Human Vaccine Adjuvants
11 GLOBAL VACCINE ADJUVANTS MARKET, BY END USER
11.1 Introduction
11.2 Research Institutes
11.3 Pharmaceutical Companies
11.4 Contract Manufacturing Organization
11.5 Commercial
11.6 Pediatric
11.7 Adults
11.8 Other End Users
12 GLOBAL VACCINE ADJUVANTS MARKET, BY GEOGRAPHY
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Chile
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.2 UAE
12.6.3 Qatar
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 KEY DEVELOPMENTS
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 COMPANY PROFILING
14.1 Viscogel AB
14.2 Vaxliant
14.3 Vaxine Pty Ltd.
14.4 Sigma Aldrich (Merck KGaA)
14.5 Sergeant Adjuvants
14.6 OZ Biosciences
14.7 Novavax, Inc.
14.8 Novartis/CSL
14.9 MVP Laboratories, Inc.
14.10 Kineta, Inc.
14.11 Invivogen
14.12 GSK
14.13 CureVac AG
14.14 CSL Limited
14.15 Avanti Polar Lipids
14.16 Aphios Corp.
14.17 Agenus, Inc.
14.18 Adjuvatis
14.19 Adjuvance Technologies, Inc
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Futuristic Market Scenario
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL VACCINE ADJUVANTS MARKET, BY PRODUCT
5.1 Introduction
5.2 Pathogen Components
5.3 Particulate Adjuvants
5.4 Combination Adjuvants
5.5 Adjuvant Emulsions
5.6 Saponin
5.7 Other Types
6 GLOBAL VACCINE ADJUVANTS MARKET, BY DISEASE TYPE
6.1 Introduction
6.2 Cancer
6.3 Infectious Diseases
6.4 Other Disease Types
7 GLOBAL VACCINE ADJUVANTS MARKET, BY TYPE
7.1 Introduction
7.2 Virus-like Particles
7.3 Tensoactive Adjuvants
7.4 Organic Adjuvants
7.5 Mineral Salt based Adjuvants
7.6 Liposomes
7.7 Emulsions
7.8 Carbohydrates Adjuvants
7.9 Bacteria-derived Adjuvants
7.10 Other Types
8 GLOBAL VACCINE ADJUVANTS MARKET, BY MECHANISM OF ACTION
8.1 Introduction
8.2 Vehicle Adjuvants
8.3 Carriers
8.4 Active Immunostimulants
9 GLOBAL VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION
9.1 Introduction
9.2 Subcutaneous Route
9.3 Oral Route
9.4 Intranasal Route
9.5 Intramuscular Route
9.6 Intradermal Route
9.7 Other Route of Administrations
10 GLOBAL VACCINE ADJUVANTS MARKET, BY APPLICATION
10.1 Introduction
10.2 Veterinary Vaccine Adjuvants
10.3 Human Vaccine Adjuvants
11 GLOBAL VACCINE ADJUVANTS MARKET, BY END USER
11.1 Introduction
11.2 Research Institutes
11.3 Pharmaceutical Companies
11.4 Contract Manufacturing Organization
11.5 Commercial
11.6 Pediatric
11.7 Adults
11.8 Other End Users
12 GLOBAL VACCINE ADJUVANTS MARKET, BY GEOGRAPHY
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Chile
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.2 UAE
12.6.3 Qatar
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 KEY DEVELOPMENTS
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 COMPANY PROFILING
14.1 Viscogel AB
14.2 Vaxliant
14.3 Vaxine Pty Ltd.
14.4 Sigma Aldrich (Merck KGaA)
14.5 Sergeant Adjuvants
14.6 OZ Biosciences
14.7 Novavax, Inc.
14.8 Novartis/CSL
14.9 MVP Laboratories, Inc.
14.10 Kineta, Inc.
14.11 Invivogen
14.12 GSK
14.13 CureVac AG
14.14 CSL Limited
14.15 Avanti Polar Lipids
14.16 Aphios Corp.
14.17 Agenus, Inc.
14.18 Adjuvatis
14.19 Adjuvance Technologies, Inc
LIST OF TABLES
Table 1 Global Vaccine Adjuvants Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Vaccine Adjuvants Market Outlook, By Product (2016-2026) (US $MN)
Table 3 Global Vaccine Adjuvants Market Outlook, By Pathogen Components (2016-2026) (US $MN)
Table 4 Global Vaccine Adjuvants Market Outlook, By Particulate Adjuvants (2016-2026) (US $MN)
Table 5 Global Vaccine Adjuvants Market Outlook, By Combination Adjuvants (2016-2026) (US $MN)
Table 6 Global Vaccine Adjuvants Market Outlook, By Adjuvant Emulsions (2016-2026) (US $MN)
Table 7 Global Vaccine Adjuvants Market Outlook, By Saponin (2016-2026) (US $MN)
Table 8 Global Vaccine Adjuvants Market Outlook, By Other Types (2016-2026) (US $MN)
Table 9 Global Vaccine Adjuvants Market Outlook, By Disease Type (2016-2026) (US $MN)
Table 10 Global Vaccine Adjuvants Market Outlook, By Cancer (2016-2026) (US $MN)
Table 11 Global Vaccine Adjuvants Market Outlook, By Infectious Diseases (2016-2026) (US $MN)
Table 12 Global Vaccine Adjuvants Market Outlook, By Other Disease Types (2016-2026) (US $MN)
Table 13 Global Vaccine Adjuvants Market Outlook, By Type (2016-2026) (US $MN)
Table 14 Global Vaccine Adjuvants Market Outlook, By Virus-like Particles (2016-2026) (US $MN)
Table 15 Global Vaccine Adjuvants Market Outlook, By Tensoactive Adjuvants (2016-2026) (US $MN)
Table 16 Global Vaccine Adjuvants Market Outlook, By Organic Adjuvants (2016-2026) (US $MN)
Table 17 Global Vaccine Adjuvants Market Outlook, By Mineral Salt based Adjuvants (2016-2026) (US $MN)
Table 18 Global Vaccine Adjuvants Market Outlook, By Liposomes (2016-2026) (US $MN)
Table 19 Global Vaccine Adjuvants Market Outlook, By Emulsions (2016-2026) (US $MN)
Table 20 Global Vaccine Adjuvants Market Outlook, By Carbohydrates Adjuvants (2016-2026) (US $MN)
Table 21 Global Vaccine Adjuvants Market Outlook, By Bacteria-derived Adjuvants (2016-2026) (US $MN)
Table 22 Global Vaccine Adjuvants Market Outlook, By Other Types (2016-2026) (US $MN)
Table 23 Global Vaccine Adjuvants Market Outlook, By Mechanism of action (2016-2026) (US $MN)
Table 24 Global Vaccine Adjuvants Market Outlook, By Vehicle Adjuvants (2016-2026) (US $MN)
Table 25 Global Vaccine Adjuvants Market Outlook, By Carriers (2016-2026) (US $MN)
Table 26 Global Vaccine Adjuvants Market Outlook, By Active Immunostimulants (2016-2026) (US $MN)
Table 27 Global Vaccine Adjuvants Market Outlook, By Route of Administration (2016-2026) (US $MN)
Table 28 Global Vaccine Adjuvants Market Outlook, By Subcutaneous Route (2016-2026) (US $MN)
Table 29 Global Vaccine Adjuvants Market Outlook, By Oral Route (2016-2026) (US $MN)
Table 30 Global Vaccine Adjuvants Market Outlook, By Intranasal Route (2016-2026) (US $MN)
Table 31 Global Vaccine Adjuvants Market Outlook, By Intramuscular Route (2016-2026) (US $MN)
Table 32 Global Vaccine Adjuvants Market Outlook, By Intradermal Route (2016-2026) (US $MN)
Table 33 Global Vaccine Adjuvants Market Outlook, By Other Route of Administrations (2016-2026) (US $MN)
Table 34 Global Vaccine Adjuvants Market Outlook, By Application (2016-2026) (US $MN)
Table 35 Global Vaccine Adjuvants Market Outlook, By Veterinary Vaccine Adjuvants (2016-2026) (US $MN)
Table 36 Global Vaccine Adjuvants Market Outlook, By Human Vaccine Adjuvants (2016-2026) (US $MN)
Table 37 Global Vaccine Adjuvants Market Outlook, By End User (2016-2026) (US $MN)
Table 38 Global Vaccine Adjuvants Market Outlook, By Research Institutes (2016-2026) (US $MN)
Table 39 Global Vaccine Adjuvants Market Outlook, By Pharmaceutical Companies (2016-2026) (US $MN)
Table 40 Global Vaccine Adjuvants Market Outlook, By Contract Manufacturing Organization (2016-2026) (US $MN)
Table 41 Global Vaccine Adjuvants Market Outlook, By Commercial (2016-2026) (US $MN)
Table 42 Global Vaccine Adjuvants Market Outlook, By Pediatric (2016-2026) (US $MN)
Table 43 Global Vaccine Adjuvants Market Outlook, By Adults (2016-2026) (US $MN)
Table 44 Global Vaccine Adjuvants Market Outlook, By Other End Users (2016-2026) (US $MN)
NOTE: Tables for North America, Europe, Asia Pacific, South America, and Middle East & Africa are represented in the same manner above.
Table 1 Global Vaccine Adjuvants Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Vaccine Adjuvants Market Outlook, By Product (2016-2026) (US $MN)
Table 3 Global Vaccine Adjuvants Market Outlook, By Pathogen Components (2016-2026) (US $MN)
Table 4 Global Vaccine Adjuvants Market Outlook, By Particulate Adjuvants (2016-2026) (US $MN)
Table 5 Global Vaccine Adjuvants Market Outlook, By Combination Adjuvants (2016-2026) (US $MN)
Table 6 Global Vaccine Adjuvants Market Outlook, By Adjuvant Emulsions (2016-2026) (US $MN)
Table 7 Global Vaccine Adjuvants Market Outlook, By Saponin (2016-2026) (US $MN)
Table 8 Global Vaccine Adjuvants Market Outlook, By Other Types (2016-2026) (US $MN)
Table 9 Global Vaccine Adjuvants Market Outlook, By Disease Type (2016-2026) (US $MN)
Table 10 Global Vaccine Adjuvants Market Outlook, By Cancer (2016-2026) (US $MN)
Table 11 Global Vaccine Adjuvants Market Outlook, By Infectious Diseases (2016-2026) (US $MN)
Table 12 Global Vaccine Adjuvants Market Outlook, By Other Disease Types (2016-2026) (US $MN)
Table 13 Global Vaccine Adjuvants Market Outlook, By Type (2016-2026) (US $MN)
Table 14 Global Vaccine Adjuvants Market Outlook, By Virus-like Particles (2016-2026) (US $MN)
Table 15 Global Vaccine Adjuvants Market Outlook, By Tensoactive Adjuvants (2016-2026) (US $MN)
Table 16 Global Vaccine Adjuvants Market Outlook, By Organic Adjuvants (2016-2026) (US $MN)
Table 17 Global Vaccine Adjuvants Market Outlook, By Mineral Salt based Adjuvants (2016-2026) (US $MN)
Table 18 Global Vaccine Adjuvants Market Outlook, By Liposomes (2016-2026) (US $MN)
Table 19 Global Vaccine Adjuvants Market Outlook, By Emulsions (2016-2026) (US $MN)
Table 20 Global Vaccine Adjuvants Market Outlook, By Carbohydrates Adjuvants (2016-2026) (US $MN)
Table 21 Global Vaccine Adjuvants Market Outlook, By Bacteria-derived Adjuvants (2016-2026) (US $MN)
Table 22 Global Vaccine Adjuvants Market Outlook, By Other Types (2016-2026) (US $MN)
Table 23 Global Vaccine Adjuvants Market Outlook, By Mechanism of action (2016-2026) (US $MN)
Table 24 Global Vaccine Adjuvants Market Outlook, By Vehicle Adjuvants (2016-2026) (US $MN)
Table 25 Global Vaccine Adjuvants Market Outlook, By Carriers (2016-2026) (US $MN)
Table 26 Global Vaccine Adjuvants Market Outlook, By Active Immunostimulants (2016-2026) (US $MN)
Table 27 Global Vaccine Adjuvants Market Outlook, By Route of Administration (2016-2026) (US $MN)
Table 28 Global Vaccine Adjuvants Market Outlook, By Subcutaneous Route (2016-2026) (US $MN)
Table 29 Global Vaccine Adjuvants Market Outlook, By Oral Route (2016-2026) (US $MN)
Table 30 Global Vaccine Adjuvants Market Outlook, By Intranasal Route (2016-2026) (US $MN)
Table 31 Global Vaccine Adjuvants Market Outlook, By Intramuscular Route (2016-2026) (US $MN)
Table 32 Global Vaccine Adjuvants Market Outlook, By Intradermal Route (2016-2026) (US $MN)
Table 33 Global Vaccine Adjuvants Market Outlook, By Other Route of Administrations (2016-2026) (US $MN)
Table 34 Global Vaccine Adjuvants Market Outlook, By Application (2016-2026) (US $MN)
Table 35 Global Vaccine Adjuvants Market Outlook, By Veterinary Vaccine Adjuvants (2016-2026) (US $MN)
Table 36 Global Vaccine Adjuvants Market Outlook, By Human Vaccine Adjuvants (2016-2026) (US $MN)
Table 37 Global Vaccine Adjuvants Market Outlook, By End User (2016-2026) (US $MN)
Table 38 Global Vaccine Adjuvants Market Outlook, By Research Institutes (2016-2026) (US $MN)
Table 39 Global Vaccine Adjuvants Market Outlook, By Pharmaceutical Companies (2016-2026) (US $MN)
Table 40 Global Vaccine Adjuvants Market Outlook, By Contract Manufacturing Organization (2016-2026) (US $MN)
Table 41 Global Vaccine Adjuvants Market Outlook, By Commercial (2016-2026) (US $MN)
Table 42 Global Vaccine Adjuvants Market Outlook, By Pediatric (2016-2026) (US $MN)
Table 43 Global Vaccine Adjuvants Market Outlook, By Adults (2016-2026) (US $MN)
Table 44 Global Vaccine Adjuvants Market Outlook, By Other End Users (2016-2026) (US $MN)
NOTE: Tables for North America, Europe, Asia Pacific, South America, and Middle East & Africa are represented in the same manner above.
